Atovaquone - Moligand™, 10mM in DMSO , CAS No.95233-18-4

CAS: 95233-18-4 Cat. No.: A409047 Peso molecular: 366.84 Número EC: 630-425-2

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

Atavaquone | 1,4-Naphthalenedione, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

Information

Atovaquone (Atavaquone) is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.
In vitro

Atovaquone (atavaquone) is a chemical compound that belongs to the class of naphthalenes. Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of ubiquinone, with antipneumocystic activity. Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket.

In vivo

Atovaquone is a unique naphthoquinone with broad-spectrum antiprotozoal activity. It is effective for the treatment and prevention of Pneumocystis carinii pneumonia (PCP), it is effective in combination with proguanil for the treatment and prevention of malaria, and it is effective in combination with azithromycin for the treatment of babesiosis.
Cell Data

cell lines：MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3, and DND-41 cell lines

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Sinónimos

Atavaquone | 1, 4-Naphthalenedione, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-

Especificaciones y pureza

Moligand™, 10mM in DMSO

Mecanismos bioquímicos y fisiológicos

Atovaquone (Atavaquone) is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.

Condiciones de almacenamiento de almacenamiento

Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

INHIBITOR

Nombres e identificadores

• Isómeros SMILES: C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O
• WGK Alemania: 3
• RTECS: QJ5616500
• Peso molecular: 366.84
• Reaxy-Rn: 21564253
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=21564253&ln=

Propiedades químicas y físicas

• Solubilidad: Solubility (25°C) In vitro Water: 100 mg/mL (757.17 mM); DMSO: 26 mg/mL (196.86 mM)
• Punto de fusión (°C): 223 °C

Referencias

1. Liu Bin, Zheng Xin, Li Jiajun, Yao Peng, Guo Peng, Liu Wei, Zhao Gaoping.  (2023)  Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway.  BMC CANCER,  23  (1): (1-13).  [PMID:37932661] [10.1186/s12885-023-11585-9]

2. Yifan Zhao, Min Zhang, Bai Lv, Guanghe Xue, Huimei Jiang, Gang Chen, Yi Ma, Yong Sun, Jie Cao.  (2023)  “Closed-Loop” O2-Economizer Induced In Situ Therapeutic Vaccine against Hypoxic Tumors.  ACS Nano,      [PMID:37877944] [10.1021/acsnano.3c05034]

3. Wenzhe Yang, Xue Pan, Peng Zhang, Xue Yang, Huashi Guan, Huan Dou, Qian Lu.  (2023)  Defeating Melanoma Through a Nano-Enabled Revision of Hypoxic and Immunosuppressive Tumor Microenvironment.  International Journal of Nanomedicine,      [PMID:37435153] [10.2147/IJN.S414882]

4. Wenhao Gao, Jialiang Zhang, Weifeng Wang, Zhihong Liu, Mulan Chen, Xiaomu Hu, Lingjun Zeng, Changqing Zheng, Hongtao Song, Qian Zhang.  (2022)  Drug self-delivery nanorods enhance photodynamic therapy of triple-negative breast cancer by inhibiting oxidative phosphorylation.  INTERNATIONAL JOURNAL OF PHARMACEUTICS,      [PMID:35489603] [10.1016/j.ijpharm.2022.121775]

5. Dan Wang, Bin Xue, Tymish Y. Ohulchanskyy, Yubin Liu, Artem Yakovliev, Roman Ziniuk, Mengze Xu, Jun Song, Junle Qu, Zhen Yuan.  (2020)  Inhibiting tumor oxygen metabolism and simultaneously generating oxygen by intelligent upconversion nanotherapeutics for enhanced photodynamic therapy.  BIOMATERIALS,      [PMID:32388167] [10.1016/j.biomaterials.2020.120088]

6. Donglin Xia, Peipei Xu, Xingyu Luo, Jianfeng Zhu, Haiying Gu, Da Huo, Yong Hu.  (2019)  Overcoming Hypoxia by Multistage Nanoparticle Delivery System to Inhibit Mitochondrial Respiration for Photodynamic Therapy.  ADVANCED FUNCTIONAL MATERIALS,  29  (13): (1807294).  [PMID:] [10.1002/adfm.201807294]

7. Enqin Zheng, Wenhao Gao, Qingyu Lu, Xiaoliang Deng, Shiting Xu, Zhihong Liu, Lingjun Zeng, Linlin Liu, Qian Zhang, Hongtao Song.  (2025)  Self-assembled metal-coordinated nanoparticles for synergistic energy metabolism inhibition and low-temperature photothermal therapy.  INTERNATIONAL JOURNAL OF PHARMACEUTICS,      [PMID:40089042] [10.1016/j.ijpharm.2025.125467]

8. Xiaoliang Deng, Xianquan Feng, Xiaohui Tang, Zhihui Zheng, Da Zheng, Enqin Zheng, Lingjun Zeng, Shiying Xu, Boxin Chen, Qian Zhang, Zhihong Liu, Hongtao Song.  (2025)  Self-Delivery Nanotherapeutics for Tumor Low-Temperature Photothermal Immunotherapy through Cascade Heat Shock Protein and Inflammation Inhibition.  ACS Applied Materials & Interfaces,      [PMID:40735962] [10.1021/acsami.5c10905]

9. Yilin Wang, Wenting Cheng, Yang Chen, Hailong Tian, Canhua Huang, Ka Li.  (2025)  Endoplasmic reticulum-mitochondria dual-targeting nanoplatform suppresses cancer stemness and enhances colorectal cancer immunotherapy.  JOURNAL OF CONTROLLED RELEASE,      [PMID:40945535] [10.1016/j.jconrel.2025.114230]

10. Shiying Xu, Lina Wu, Boxin Chen, Xiaoliang Deng, Zhihui Zheng, Fei Wu, Lingjun Zeng, Changqing Zheng, Xiaomu Hu, Aiwen Huang, Xin Zhou, Xianquan Feng, Zhihong Liu.  (2025)  A self-delivery albumin nanomedicine amplified photodynamic therapy against esophageal cancer through COX-2/PGE2 interruption and regulation of mitochondrial respiratory.  International Journal of Pharmaceutics-X,      [PMID:41089759] [10.1016/j.ijpx.2025.100407]